Movement Alert｜Innovent Biologics Falls 3.59% in Regular Trading, Pfizer Deal Regulatory Approval Uncertainty Continues to Weigh on Stock

Market Focus

Jun 08

On June 8, Innovent Biologics fell 3.59% in regular trading, trading at 74.6 HKD/share, with trading volume of HKD 243 million. The stock has declined for multiple consecutive trading sessions following its 11% surge on May 29 when the company announced a USD 10.5 billion global strategic collaboration with Pfizer.

Market concerns continue to center on whether the landmark transaction can obtain the necessary regulatory approvals. Recent speculation around potential revisions to biomedical export control lists and the US COINS Act's potential restrictions on biotechnology have intensified doubts about deal completion, persistently suppressing investor sentiment. The collaboration covers 12 early-stage oncology projects including ADCs and multispecific antibodies, with Innovent receiving USD 650 million upfront and up to USD 9.85 billion in milestone payments.

Within the Biotechnology sector, partial weakness in peer stocks added pressure, with 3SBio down 2.81% and Akeso down 1.18%, creating a resonance drag on Innovent Biologics.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1130279384"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130279384\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130279384?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130279384","market":"us","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Falls 3.59% in Regular Trading, Pfizer Deal Regulatory Approval Uncertainty Continues to Weigh on Stock","media":"Market Focus","content":"<p><p>On June 8, Innovent Biologics fell 3.59% in regular trading, trading at 74.6 HKD/share, with trading volume of HKD 243 million. The stock has declined for multiple consecutive trading sessions following its 11% surge on May 29 when the company announced a USD 10.5 billion global strategic collaboration with Pfizer.</p><p>Market concerns continue to center on whether the landmark transaction can obtain the necessary regulatory approvals. Recent speculation around potential revisions to biomedical export control lists and the US COINS Act's potential restrictions on biotechnology have intensified doubts about deal completion, persistently suppressing investor sentiment. The collaboration covers 12 early-stage oncology projects including ADCs and multispecific antibodies, with Innovent receiving USD 650 million upfront and up to USD 9.85 billion in milestone payments.</p><p>Within the Biotechnology sector, partial weakness in peer stocks added pressure, with 3SBio down 2.81% and Akeso down 1.18%, creating a resonance drag on Innovent Biologics.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Falls 3.59% in Regular Trading, Pfizer Deal Regulatory Approval Uncertainty Continues to Weigh on Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Falls 3.59% in Regular Trading, Pfizer Deal Regulatory Approval Uncertainty Continues to Weigh on Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-08 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 8, Innovent Biologics fell 3.59% in regular trading, trading at 74.6 HKD/share, with trading volume of HKD 243 million. The stock has declined for multiple consecutive trading sessions following its 11% surge on May 29 when the company announced a USD 10.5 billion global strategic collaboration with Pfizer.</p><p>Market concerns continue to center on whether the landmark transaction can obtain the necessary regulatory approvals. Recent speculation around potential revisions to biomedical export control lists and the US COINS Act's potential restrictions on biotechnology have intensified doubts about deal completion, persistently suppressing investor sentiment. The collaboration covers 12 early-stage oncology projects including ADCs and multispecific antibodies, with Innovent receiving USD 650 million upfront and up to USD 9.85 billion in milestone payments.</p><p>Within the Biotechnology sector, partial weakness in peer stocks added pressure, with 3SBio down 2.81% and Akeso down 1.18%, creating a resonance drag on Innovent Biologics.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1130279384","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130279384","pubTimestamp":1780883505,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 8, Innovent Biologics fell 3.59% in regular trading, trading at 74.6 HKD/share, with trading volume of HKD 243 million. The stock has declined for multiple consecutive trading sessions...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动向提示|信达生物常规交易跌3.59%辉瑞交易监管审批不确定性持续打压股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On June 8, Innovent Biologics fell 3.59% in regular trading, trading at 74.6 HKD/share, with trading volume of HKD 243 million. The stock has declined for multiple consecutive trading sessions following its 11% surge on May 29 when the company announced a USD 10.5 billion global strategic collaboration with Pfizer.Market concerns continue to center on whether the landmark transaction can obtain the necessary regulatory approvals. Recent speculation around potential revisions to biomedical export control lists and the US COINS Act's potential restrictions on biotechnology have intensified doubts about deal completion, persistently suppressing investor sentiment. The collaboration covers 12 early-stage oncology projects including ADCs and multispecific antibodies, with Innovent receiving USD 650 million upfront and up to USD 9.85 billion in milestone payments.Within the Biotechnology sector, partial weakness in peer stocks added pressure, with 3SBio down 2.81% and Akeso down 1.18%, creating a resonance drag on Innovent Biologics.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}